Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
- Author(s)
- Döhner, H; DiNardo, CD; Appelbaum, FR; Craddock, C; Dombret, H; Ebert, BL; Fenaux, P; Godley, LA; Hasserjian, RP; Larson, RA; Levine, RL; Miyazaki, Y; Niederwieser, D; Ossenkoppele, G; Röllig, C; Sierra, J; Stein, EM; Tallman, MS; Tien, HF; Wang, J; Wierzbowska, A; Wei, AH; Löwenberg, B;
- Details
- Publication Year 2024-11-21,Volume 144,Issue #21,Page 2169-2173
- Journal Title
- Blood
- Publication Type
- Guideline
- Abstract
- The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
- Publisher
- American Society of Hematology
- Keywords
- Humans; *Leukemia, Myeloid, Acute/genetics/therapy/drug therapy; Adult; Risk Assessment; Genetic Predisposition to Disease; Risk Factors
- Department(s)
- Haematology
- Publisher's Version
- https://doi.org/10.1182/blood.2024025409
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-12-10 07:11:39
Last Modified: 2024-12-10 07:11:53